Inhalable Anti-EGFR Antibody-Conjugated Osimertinib Liposomes for Non-Small Cell Lung Cancer

Inhalable Anti-EGFR Antibody-Conjugated Osimertinib Liposomes for Non-Small Cell Lung Cancer

<b>Background</b>: Non-small cell lung cancer (NSCLC) is a leading cause of cancer deaths globally. The most extensive treatment is Tyrosine Kinase Inhibitors (TKIs) that target epidermal growth factor receptor (EGFR) overexpression. Osimertinib, a third-generation TKI is approved to tar...

Full description

Saved in:
Bibliographic Details
Main Authors: Apoorva Daram, Shruti S. Sawant, Dhwani A. Mehta, Carlos A. Sanhueza, Nitesh K. Kunda
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Pharmaceutics
Subjects:
non-small cell lung cancer
osimertinib
cetuximab
immunoliposomes
inhalation therapy
Online Access:https://www.mdpi.com/1999-4923/16/11/1444
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1999-4923/16/11/1444

Similar Items